Objective. To investigate maintenance of rituximab (RTX) in RA patients re-treated with reduced doses compared with standard dose in a real life setting.
Introduction
B cell depletion obtained with rituximab (RTX) is an established and effective treatment for RA. In combination with MTX, RTX has been shown to significantly reduce clinical signs and symptoms of RA and inhibit structural damage progression, in either MTX naïve [1, 2] or inadequate responders to conventional DMARDs (DMARDs) [3] or anti-TNF RA patients [4] .
According to its licence, RTX should be administered intravenously at the dose of 1000 mg for two infusions given 2 weeks apart, and associated with intravenous glucocorticoid premedication and concomitant MTX. In responders, the need for retreatment should be evaluated 24 weeks after the previous course and a new course of RTX should be given, using the same schedule (1000 mg Â 2), if residual disease activity remains.
In randomized controlled trials (RCTs), conducted in MTX-inadequate responders and MTX-naïve patients, clinical efficacy of reduced doses of RTX (500 mg Â 2), given either since the first course or reduced only at retreatment, did not differ from that of standard doses [1, 2, 58] in terms of reduction of disease activity. However, in early RA, when the reduced dose was given since the first course, structural progression was slightly more pronounced than with the standard dose, during the first 6 months of treatment, this difference being no more significant after 1 and 2 years of follow-up [1] . Recently, the non-inferiority SMART (Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy) trial compared, the efficacy of a retreatment at reduced dose (one infusion of 1000 mg) given after a first course of RTX at standard dose to a retreatment at standard doses and demonstrated the similar clinical efficacy of both regimens at 2 years [8] . Interestingly, the recent ORBIT trial demonstrated that a first line biologic with standard dose of RTX was non-inferior to anti-TNF in terms of clinical efficacy but was cost-saving over 12 months. Thus, if retreatment could be administered at reduced dose with the same efficacy, the decrease of the cost of this treatment could be even more important [9, 10] .
Finally, another point of interest of the long-term use of reduced doses of RTX is potentially a better safety profile, particularly an expected lower risk of infections. Thus, the objective of the present study was to compare the efficacy and safety of retreatment with reduced doses of RTX with that of standard doses in RA patients treated with RTX in a real life setting.
Methods

Patients
The Autoimmunity and Rituximab (AIR) registry is a nationwide prospective cohort study investigating the long-term safety and efficacy of RTX in RA patients according to ACR criteria [11] . Its methodology has been previously reported [12] . This study was approved by the French authorities (Comité Consultatif sur le Traitement de l'information en matiè re de Recherche dans le domaine de la Santé and Commission Nationale de l'Informatique et des Liberté s). An informed consent was obtained from all patients.
Among the 1986 RA patients from the AIR registry, we included in the present study those that were re-treated at least once with RTX whatever the dose, at least 24 weeks after a first course administered at the standard dose (1000 mg Â 2) and that had at least 6 months of followup after this first retreatment.
RTX regimens
Two groups were defined according to RTX retreatment regimens. The standard dose group (A) included patients re-treated with a standard dose (1000 mg Â 2) at the first course of retreatment. The reduced dose group (B) included patients that have received a reduced dose at the first course of retreatment. All courses of RTX given with a total dose lower than 2000 mg were considered as reduced dose.
In this observational study, the choice of the retreatment dose was not imposed but was decided by the physician in charge of the patient in the context of care. Therefore, some patients have not received the same dose for all retreatment courses, and doses might have been further increased or decreased. Since, the objective was to compare two strategies of retreatment, i.e. use of reduced dose since the first course of retreatment vs standard dose, for all analyses the patients remained in their initial groups.
Study outcomes
The primary outcome was the maintenance of RTX at 5 years from the first day of the second course of RTX (first retreatment course). Treatment failure or non-maintenance was defined by a consensus of the scientific committee of the registry as either death, discontinuation of RTX due to side effect or lack of efficacy. Lack of efficacy was defined as a switch to another biologic agent, or the introduction of a combination of DMARDs, or an increase in corticosteroid dose (510 mg at two consecutive visits) or mention of lack of efficacy according to the physician's judgement.
Secondary efficacy outcomes included reasons of treatment failure; the number of retreatment courses; the mean time between courses; and the EULAR response at 1 and 2 years after the beginning of retreatement, that is approximately 18 and 30 months after initiation of RTX. The EULAR response rates were not reported later, because the healthy drug survival effect bias increases with time since these analyses only include patients continuing treatment. Also, the cumulative dose of RTX expressed in milligrams per year was calculated by dividing the total dose of RTX calculated by summing all received doses by the treatment duration for each patient to estimate the magnitude of dose reduction in the reduced dose group. Treatment duration was defined by the time between the first day of first retreatment course (the first course of RTX was excluded) and either the end of follow-up (censored at 5 years after the first retreatment if follow-up was >5 years) or the time of treatment discontinuation or 24 weeks after the last RTX infusion in case of shorter follow-up after the last infusion.
Safety analyses focused on the rate of serious infections. Infections were defined as serious if patients were hospitalized due to their infection and/or received intravenous antibiotics or died.
Statistical analysis
Continuous variables are reported as the mean (S.D.) or median (range) and were compared using Student's t-test or Wilcoxon's rank sum test, as appropriate. Categorical variables are reported as number and percentage and were compared by chi-square test or Fisher's exact test, as appropriate.
The primary end point was the maintenance of RTX 5 years after the second course of RTX. Maintenance of reduced dose group was analysed using the KaplanMeier method and compared with that of standard dose group using the log rank test, for the crude analysis. A marginal Cox model, which allowed the within-centre correlation (i.e. centre effect) to be taken into account, was used for adjusted analyses. Hazard ratios of maintenance and their 95% CI were obtained using the standard dose group as reference. For adjusted analyses, a propensity score was modelled for each comparison. This score included all the main RA parameters and all baseline variables that could influence the choice of the RTX dosage and/or the maintenance of treatment. These variables included sex, age at the time of inclusion, disease duration, seropositivity (defined as the presence of RF and/or ACPA), presence of bone erosions, concomitant use of MTX, number of previous biologic agents, concomitant use of corticosteroids, time between the first and second course of RTX, and DAS28 at the time of the second course of RTX. To take into account a possible period effect, we considered that the presentation at the ACR meeting of the results of the MIRROR study showing that the half-dose regimen had similar efficacy to the full dose might have influenced the use of the half-dose regimen [7] . A time period variable was added to the propensity score using as cut-off the date of this presentation (1 December 2008). Due to missing data for the DAS28, an alternative propensity score was obtained, excluding the DAS28. The main analyses used the inverse probability of treatment weighting-propensity score adjusted method. Two adjusted analyses were performed that respectively used the inverse probability of treatment weighting with the propensity score including DAS28 (model 1) and with the propensity score excluding DAS28 (model 2).
For safety analyses, the rates of serious infections were estimated by calculating the number of serious infections per person-year, from the beginning of the retreatment. Between-group comparisons of the rate of serious infections were performed using Cox proportional hazard ratio models for multiple events data. Analyses were adjusted on age, the corticosteroids dose at time of retreatment, chronic lung and/or cardiac disease, extra-articular involvement and serious infection during the first course.
For all analyses, a P < 0.05 was considered significant. All statistical analyses involved the use of the SAS release 9.4 (SAS Institute Inc., Cary, NC, USA) statistical software package.
Results
Patients
Among the 1986 RA patients from the AIR registry, 708 were excluded, mainly due to the absence of retreatment (84.5%). Of the 1278 (64.4%) patients that fulfilled inclusion criteria (Fig. 1) , 1093 (85.5%) were re-treated with standard dose (group A), and 185 (14.5%) with reduced dose at the second course (group B). In 218 (19.9%) patients of group A, RTX dose has been reduced at a later course, after a median number of 4 (313) courses of retreatment. Likewise, in 45 (24.3%) patients from group B, RTX dose has been further re-increased.
Baseline characteristics
Comparison of baseline characteristics at inclusion in the AIR registry revealed that patients included in the present study did not differ from those excluded (i.e. those not retreated) except for the prevalence of ACPA or RF positivity [1070/1184 (90.4%) vs 556/650 (85.5%), P = 0.002]. Among patients included, there was a higher proportion of males (P = 0.008), and a lower prevalence of bone erosions (64.6% vs 76.1%, P = 0.002) in the standard dose group compared with the reduced dose group (Table 1) . However, the number of previous biologics and the proportion of patients receiving concomitant synthetic DMARD or corticosteroids did not significantly differ between groups. The baseline DAS28 was 5.6 (1.3) and was not different among groups. However, the DAS28 at the time of the first retreatment was lower in the reduced dose group compared with the standard dose group [4.5 (1.3) vs 5.0 (1.3), P < 0.001].
Characteristics of retreatment by RTX
The mean number of RTX retreatment cycles (Table 2) did not differ between reduced and standard doses groups [3.5 (2.3) vs 3.4 (2.1), P = 0.61]. But, the mean time between two courses was shorter in the reduced dose group compared with the standard dose group [7.6 (3. 3) vs 8.2 (3.1) months, P = 0.004]. Also, the cumulative RTX dose in gram per year received for retreatment, was decreased by 39% in the reduced dose group compared with the standard dose group [1.4 (0.6) vs 2.3 (1.0) g/year, P < 0.001].
Maintenance of RTX at 5 years after retreatment and predictors of non-maintenance
Factor associated with non-maintenance Overall, 471 (36.9%) patients discontinued RTX. Reasons for non-maintenance were lack of efficacy in 306 (23.9%) patient (RTX discontinuation in 305 and introduction of a combination of DMARDs in one patient), safety reasons in 127 (9.9%) and death in 38 (3.0%) patients. They did not differ between groups (Table 2) .
In univariate analysis in the total population, parameters associated with non-maintenance were seronegativity (absence of RF and ACPA) (HR = 1.88; 95% CI: 1.43, 2.48), previous use of biologic agent (HR = 1.16; 95% CI: 1.07, 1.26, per additional biologic agent); DAS28 at retreatment (HR = 1.15; 95% CI: 1.05, 1.25, per additional DAS28 point); age (HR = 1.01; 95% CI: 1.002, 1.02, per additional year) and shorter time between the first two courses (HR = 0.98; 95% CI: 0.97, 0.997, per additional month). All these parameters have been included in the propensity score. These analyses also revealed a centre effect, which was taken into account by the use of a marginal model.
Comparison of the 5-year maintenance between standard and reduced dose groups
Maintenance of RTX at 5 years (see supplementary Table S1 , available at Rheumatology Online) was 55.5% (95% CI: 51.9, 59.1%) in the standard dose group, 53.8% (95% CI: 44.7, 62.1%) in the reduced group, and did not differ between the two groups in crude analysis (HR = 1.06; 95% CI: 0.82, 1.36) (Fig. 2) . In adjusted analyses using propensity score inverse ponderation weighting, maintenance of RTX in the reduced dose group did not significantly differ from the standard dose group either in the model including DAS28 [58.0% (95% CI: 46.9, 67.5) vs 57.0% (95% CI: 52.1, 61.6); adjusted HR = 1.03; 95% CI: 0.81, 1.30; P = 0.83; see supplementary Comparison of the EULAR response at 1 and 2 years between standard and reduced dose groups EULAR responses were calculated at 1 and 2 years after the beginning of the retreatment in the patients continuing treatment and was available in 428/908 and 312/731 patients of the standard group and 73/147 and 62/126 patients of the standard group at 1 and 2 years, respectively. The EULAR response rates in standard and reduced dose groups were, respectively, 65.7 and 76.7% at 1 year and
FIG. 1 Study flow chart
The standard dose group (A) included patients re-treated with a standard dose (1000 mg Â 2) at the first course of retreatment. The reduced dose group (B) included patients that had received a reduced dose at the first course of retreatment. AIR: auto immunity and rituximab; RTX: rituximab.
76.3 and 80.7% at 2 years and did not significantly differ between groups (Fig. 3) . Analyses of EULAR response at later time points did not reveal a major difference between groups but rely on < 50% of the total population in each group and should be interpreted with caution since the healthy drug survival effect bias increases with time (data not shown).
Safety
In the overall population, during the retreatment period (i.e. since the second course) 143 serious infections occurred in 120 patients. The rate of serious infections was 3.8/100 patient-years (95% CI: 3.2, 4.5). This rate was lower in the reduced dose group (2.2/100 patientyears; 95% CI: 1, 3.5) compared with the standard dose group (4.1/100 patient-years; 95% CI: 3.4, 4.8; adjusted hazard ratio = 0.50; 95% CI: 0.27, 0.92; P = 0.02) (Fig. 4) .
Of note, factors associated with risk of serious infection, such as baseline low gammaglobulin or IgG levels, chronic lung or cardiac disease and extra-articular involvement, did not differ between groups. However, the mean corticosteroid dose at the second course was slightly lower in the reduced dose group [8.1 (5.4) mg/day] compared with standard dose group [9.0 (5.9) mg/day, P = 0.045], but, did not differ between patients that experienced a serious infection and those that did not [8.7 (6.5) vs 8.9 (5.8) mg/day, P = 0.82].
Also, by contrast, during the first course of RTX, for the 1278 patients included in the present study, the rate of serious infection was lower in the patients that further received their first retreatment course at standard dose compared with those that further received reduced doses [3.09/100 patient-years (95% CI: 2.07, 4.12) vs 6.40/100 patient-years (95% CI: 2.78, 10.01); P = 0.037]. Also, the occurrence of a serious infection during this first course was associated with a significant increased risk of occurrence of a new serious infection during retreatment (adjusted hazard ratio = 3.86; 95% CI: 1.82, 8.20; P = 0.0004; after adjustment on age, dose of RTX for retreatment and the presence of chronic lung or cardiac disease and extra-articular involvement).
Discussion
This study is one of the largest real-life studies exploring the use of reduced dose of RTX in RA patients and has the longest follow-up. Our results, based on data from the AIR registry, suggest that using a reduced dose of RTX for retreatment did not alter the 5-year maintenance of Results are reported as n (%) or mean (SD) unless otherwise indicated. *Statistically significant difference between groups A and B with P < 0.05. AIR: Autoimmunity and Rituximab; RTX: rituximab.
treatment and was associated with a lower risk of serious infection compared with the use of standard dose at each RTX course. This study has some limitations that are linked to its observational design. First, such design might induce between-groups imbalance in patient characteristics. Nevertheless, comparison of patient characteristics did not reveal major differences between groups, except for the DAS 28 at the time of the first retreatment, which was higher in the standard dose group. Nevertheless, to minimize this potential bias, we performed various propensity score adjusted analyses taking into account factors that might influence treatment efficacy, such as the presence of RF or ACPA [1315] including the DAS28 at the time of retreatment. Interestingly, analyses revealed a major centre effect in the probability of receiving reduced doses for retreatment, suggesting that the chance of being treated with reduced doses is rather linked to physician/centre habits than to disease characteristics. Nevertheless, this centre effect was taken into account in adjusted analyses and therefore might not have affected estimation of treatment maintenance. Another potential limitation is the presence of missing data for some of the propensity score variables, particularly the DAS28. However, to overcome this pitfall, we constructed a propensity score with and without this variable in our adjusted models, and most of the results were consistent across all adjustments. Finally, due to the real-life nature of this study, we acknowledge that some of the usual outcome measures used in RA, such as radiographic progression or measure of function, were not available. Also, since the patient follow-up was left to the discretion of the physician in charge of the patients, all patients were not evaluated at the same time point, which is one of the reasons that led us to use maintenance as primary outcome and not a more classical efficacy end point such as EULAR response. In addition, maintenance is also a good outcome for measuring safety, since patients that remained treated with a given treatment are those that respond to it and tolerate it well.
The results of our study are consistent with those of the SMART trial that showed that following a clinical response to a first course of RTX at the licensed dose of 1000 mg Â 2, retreatment with reduced dose of RTX (1000 mg Â 1) resulted in non-inferior efficacy outcomes to those achieved with standard dose retreatment. They are also in line with those from the SERENE, IMAGE and MIRROR trials [1, 2, 6, 7] , which suggested that reduced doses (500 mg Â 2) of RTX, used as soon as the first course of RTX, had similar clinical efficacy to a standard dose. We used in our study as a secondary end point the same end point as in these studies, that is, the EULAR response 1 and 2 years after the retreatment and did not see any difference between groups. Even if in the MIRROR trial and in a recent meta-analysis [16] the efficacy tended to be higher in the standard dose group compared with reduced dose group, this differential clinical effect is borderline and might be marginal compared with pharmacoeconomic implications for health systems.
Nevertheless, we could not conclude on the structural effect of reduced dose of RTX, since, as with most registry data, we did not evaluate radiological outcome. Indeed, in the IMAGE trial, MTX-naïve RA patients treated with The rate of serious infections was lower in the reduced dose group (dotted line) compared with the standard dose group (line) (aHR = 0.46; 95% CI: 0.25, 0.87; P = 0.02). aHR: adjusted hazard ratio. standard dose (2 Â 1000 mg) had significantly less joint damage progression during the first year as compared with patients treated with the reduced dose (2 Â 500 mg). However, this difference was only observed during the first year, principally the first 6 months, and thereafter both doses of RTX significantly and similarly inhibited joint damage progression [1, 2] , suggesting that radiological progression occurs during the first months of treatment, while RA is still active and uncontrolled. Therefore, it is likely that a strategy, such as the one we studied here, with a RTX dose reduction after a response to a first course given at a standard dose might avoid this initial structural damage and therefore be associated with a similar structural effect to the standard dose.
Another strength of this study is its large sample size and its real-life setting. Compared with the other recently published real life study that analysed the effect of reduced of RTX, from the CERRERA collaboration [17] , our study analysed the effect of low doses for retreatment and not as initial treatment. Also, unlike the CERRERA study, whose duration was only of 6 months with RCTs having a maximal follow-up period of 2 years, our study provided for the first time very long-term maintenance and safety data of a reduced dose RTX regimen. Our results therefore suggest that, even in the long-term, reduced and standard doses seem to a have similar effectiveness. Also, it must be noticed that the dose of RTX had been further increased in nearly a quarter of the patients of the reduced dose group, but a similar proportion of the patients of the full dose switch to the half-dose during followup. All these patients remained in their initial group for analysis since our objective was to compare two strategies, but we acknowledge that this crossover might have minimized the potential between group differences, if any.
In the standard dose group, RTX was administered with an interval between two infusions longer than the licensed dose [median interval of 7.8 (6.09.7) months], suggesting that systematic retreatment at 6 months is not mandatory. Thus, even at standard dose, real life use of RTX already results in a decreased cumulative dose and thus cost, making RTX one of the cheaper biologic therapies, and it will be even cheaper with the arrival of the biosimilars of the drug [9, 10] . In addition, even if the use of a reduced dose was associated with a slight reduction of interval between infusions [median interval of 6.9 (5.58.7) months], this strategy induced a decrease of cumulative dose by nearly 40% compared with the standard dose group, but a 65% decrease compared with a systematic full dose retreatment every 6 months, resulting in a significant economic benefit.
In addition to this economic benefit, in the present study we observed for the first time a significant decreased risk of serious infections with the reduced dose strategy compared with the standard dose, which has never been shown before. A meta-analysis of the RCT comparing standard and reduced doses of RTX in RA also found a non-significant reduction of the risk of serious infection with a risk ratio of 0.73 (0.371.47) (P = 0.38) [18] . For the first time, due to its real-life nature, the present study has a larger sample size and a longer follow-up than a RCT to examine such an effect. Nevertheless, we included patients having received a second course of RTX and therefore selected those that tolerated and responded to a first cycle. Patients of the reduced dose group had a lower disease activity and a slightly lower corticosteroid dose at the time of the first retreatment, which could be associated with a lower rate of serious infections. Nevertheless, analyses have been adjusted on dose of corticosteroids and other factors found to be associated with an increased risk of infection in the AIR registry [12] . Also, patients of the reduced dose group had a 2-fold increased rate of serious infection after the first course of RTX and thus were more prone to have a second infection, which might have negatively impacted the safety profile of the reduced dose. Finally, we could not exclude an under-reporting of adverse events due to the observational nature of the study. Nevertheless, it is unlikely that this affects differently the different treatment groups.
In conclusion, use of reduced doses of RTX for retreatment in RA patients did not alter the maintenance of the treatment at 5 years and is associated with a significant lower rate of serious infections. In addition, with its better safety profile, such a strategy allows a 40% dose reduction compared with the standard dose strategy and 65% compared with a systematic full dose retreatment every 6 months, which is greatly cost-effective.
